Johnson & Johnson beats Mylan over Levaquin

A Dec. 24 Reuters report noted the beneficial impact on the stock price of Daiichi concerning the win of Johnson & Johnson (J&J) over Mylan:

-->Daiichi Pharmaceutical surged 3.5 percent to 2,210 yen after it and partner Johnson and Johnson won a patent suit on antibiotic Levaquin, delaying until 2010 plans by Mylan Laboratories Inc. to sell a generic version of the drug.<--